identified ARID1A as a candidate tumor suppressor gene (TSG) in breast cancer (BC) by an integrated genomic approach. They reported loss of heterozygosity of the ARID1A locus at 1p36.11 in 13% of 82 analyzed BC samples, and an ARID1A nonsense mutation in one out of five BC cell lines. However, they did not find any ARID1A mutation in 11 analyzed BC samples. Low ARID1A RNA expression and nuclear protein expression were associated with aggressive BC phenotypes in two series of B250 samples.
We examined the genomic profiles of 256 breast tumors established by comparative genomic hybridization (244K CGH Microarray, Agilent Technologies, Massy, France). The 1p36.11 region was targeted by heterozygous or homozygous losses in 40% and 3.5% of samples, respectively. Within this region, we found ARID1A heterozygous and homozygous loss in 35.2% and 2% of cases, respectively. We looked at ARID1A expression in the 256 BC samples profiled by Affymetrix microarrays. ARID1A deletions were associated with mRNA downregulation (P ¼ 1.23 Â 10 À6 , Student's ttest) (not shown), suggesting that ARID1A haploinsufficiency may have a role in BC. In a series of 2609 invasive BC from 15 public microarray data sets, lower ARID1A gene expression was associated (Po0.05, Student's t-test) with advanced clinical stage (III-IV vs II vs I), high grade (3 vs 2 vs 1), ER-negativity, PRnegativity, ERBB2-positivity and poor-prognosis molecular subtypes (basal vs ERBB2 vs luminal B vs others).
To determine whether ARID1A was also targeted by mutations, we Sanger-sequenced the 20 exons of the gene in 95 BC samples, as described (Birnbaum et al., 2011) . Three cases showed a heterozygous mutation (one frameshift, one nonsense and one missense) (Figure 1 ). These three tumors did not show ARID1A gene copy number loss. Gene expression profiles, available for two of them, did not show ARID1A mRNA deregulation compared with normal breast tissues.
ARID1A encodes a subunit of the SWI/SNF chromatin-remodeling complex. It is mutated in B50% of ovarian clear-cell carcinomas, 30% of endometriosis-associated ovarian carcinomas (Jones et al., 2010; Wiegand et al., 2010) and 40% of uterine low-grade endometrioid carcinoma (Guan et al., 2012) . ARID1A was deleted and mutated in BC at about the same frequency as in pancreatic cancer (Birnbaum et al., 2011) . A recent study of several tumor types identified 4 mutations in 114 cases of BC (Jones et al., 2012) . Mamo et al. probably sequenced too few BC samples to find a mutation. The c.5548dup frameshift that we observed in one breast tumor appears as the most frequent mutation (Wiegand et al., 2010; Jones et al., 2012) . These and our data confirm and extend Mamo's study and show that ARID1A may act as a TSG in various carcinomas including BC.
